Breast cancer is a complex disease characterized by the accumulation of multiple molecular alterations giving each tumor phenotype and an own evolutionary potential. This study aimed to describe the distribution of the profile and molecular subtypes of breast cancers followed at Surgical Oncology Unit of Donka National Hospital. This was retrospective and descriptive study on cases of breast cancer in which the hormone receptor status and expression of the Her2 oncogene have been performed from 2007 to 2016. We recorded 58 cases including 56 (96.6%) women and 2 (3.4%) men. The average age was 48.2 ± 10.9. Invasive ductal carcinoma accounted for 50 (86.2%) cases. The SBR grade was II in 31(53.4%) cases, III in 21 (36.2%) cases and I in 6 (10.3%) cases. The tumor was classified as T4 in 36 (62.1%) cases; it was metastatic in 11(19.0%) cases.
Introduction
Breast cancer is a major global public health problem. About 1,671,149 cases are diagnosed each year, including 521,907 deaths worldwide [1] . The number of cases reached 53,000 and more than 11,000 deaths in France [2] . In Africa, the incidence is 133,390 new cases with 63,160 deaths [1] . In North and Middle East Africa, breast cancer is the first cancer in women. It accounts for 14 to 42% of all female cancers with an exponential increase [3] . In Guinea, the agestandardized incidence is 14.5 new cases per 100,000 and the mortality rate is 7.9 per 100,000 [1] . It represents the leading cause of consultation at the Surgical Oncology Unit (SOU) of Donka National Hospital and represents 26% of all cancers [4] . In sub-Saharan countries, the patients are relatively younger and the stages are aggressive [5, 6] . Breast cancer now appears as a complex disease characterized by the accumulation of multiple molecular alterations that give each tumor a phenotype and a potential for evolution. The study of genomic alterations of tumor cells revealed their relation with the prognosis and the effectiveness of the treatments; thus requiring making a personalization in the therapeutic management. The early distinction of responder and non-responder patients is to avoid the use of ineffective chemotherapies for some patients. The progress of molecular biology techniques and gene sequencing allowed understanding the breast cancer genesis. Perou et al. [7] analyzed in 2000 the gene expression of breast cancer by micro-array and were able to highlight five molecular groups. This molecular classification distinguishes the luminal A, luminal B, Her2 positive, basal-like, and triple-negative subtypes [8] . Indeed, immunohistochemistry is used to define biological prognostic factors and especially to make a target therapy. This target therapy has been made possible through the use of monoclonal antibodies and hormone therapy. In our country, immunohistochemistry (IHC) is not available and there are very little data on the molecular profile of breast cancer [4, 9] . This study aimed to determine the first trends in the molecular profile of breast cancers followed at the surgical oncology unit of Donka National Hospital.
Methods
This was retrospective and descriptive study on cases of breast cancer in which the hormone receptor status and expression of the Her2 oncogene have been reported. These patients were followed at the Surgical Oncology Unit (SOU) of the Donka National Hospital, and SBR I in 6 cases (10.3%). The tumor stage was less than or equal to T2 in 14 cases (24.1%), and greater than T2 in 44 cases (75.9%).
There were axillary and/or subclavicular lymph nodes in 36 cases (62.1%). Locally advanced and metastatic stages were most common in 28 cases (48.3%) and 11 cases (19.0%). 
Discussion
This study highlights the dire need for IHC in sub-Saharan Africa. In this retrospective study, IHC was performed for 10.2% of breast cancers diagnosed from 2007 to 2016. Access to IHC remains limited, as it accounts for less than 30% of breast cancers in West African countries [10, 11] . It is often during study projects, whether monocentric [12] or multicenter [13] , that the molecular profile is better performed in different sub-Saharan Africa countries. On the other hand, there is better access in the Maghreb countries [14] . IHC is not available in our country as in most countries of sub-Saharan Africa. For the cases in this study, the histological diagnosis is made Intensive Care Consortium (ICC) was the common histological type in more than 80% as in several other studies in Africa and elsewhere [14, 13, 20] . However, many efforts still have to be made by Guinean pathologists as to the description of histological types. In western countries, the majority of breast tumors are less than 2cm, reflecting early detection of the disease [21] . We did not take into account the tumor size in this study but 75.9% were classified T3-T4.
These same proportions are found in multicentric studies in subSaharan Africa [22] . The advanced stage of diagnosis in our patients could be explained by the young age, the delay of consultation, the absence of mass screening in the population, the bad orientation and an insufficient reference system of the cancer patients. HRs were positive in half of the patients in our study. The positivity of HR in breast cancer remains very varied and heterogeneous in countries.
The results are similar in South Africa [23] and Ghana [11] . HR positivity is very high in the Maghreb and the Western countries, possibly exceeding 70% [24] . These differences would be related to the young age of our patients even though patients with HR positive were relatively older than patients with HR negative. HR positivity has been shown to be greater in older patients than in the elderly [25] .
HR is different depending on the types of receptors. In our study, ER were positive in 50.0% while PR were positive in 43.1%. This receptor positivity appeared to be higher than in Mali where Ly et al. [26] showed that ER and PR were positive in 39% and 29% respectively. Apart from locoregional (by surgery and radiotherapy) and systemic (by chemotherapy) control, triple negative breast cancers are very difficult to manage in case of resistance to chemotherapy due to the lack of therapeutic target. The numbers are small, which could be used to highlight the lack of services in Guinea. The number of patients treated with hormone therapy (72.0%) and trastuzumab (18.2%) are small, which could be used to highlight the lack of services in Guinea.
Conclusion
This preliminary study showed the poor accessibility of immunohistochemistry for the molecular diagnosis of breast cancer in our country. Luminal A subtypes and triple negatives were more common. The determination of molecular subtypes is a rational basis for hormone therapy and targeted therapy, thus personalizing the breast cancer treatment.
What is known about this topic
 Breast cancer in sub-Saharan African women is aggressive: triple negatives and high grades.
What this study adds
 We noted a difference in the distribution of molecular subtypes: luminal A more frequent than triple negative, but still high grade. 
